TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 363345

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (Ng)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Norgestrienone (R2010)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Copper T 200
Number of subjects: 990
Study: 31145907

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied for 16 minutes to the right posterior superior temporal cortex
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 39
Study: 28685911

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus herbal medicine (two tablets: Tablet 1 with Cinnamomum verum, Glycyrrhiza glabra, Hypericum perforatum, Paeonia lactiflora; Tablet 2 with Tribulus terrestris)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus herbal medicine
Number of subjects: 122
Study: 26587413

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 75
Study: 23798810

Group type: EXPERIMENTAL
Intervention: IPS‐ABNR repair (group B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: YDL bladder neck repair (group A)
Number of subjects: 16
Study: 21802567

Group type: EXPERIMENTAL
Intervention: Daily dark chocolate snack
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-chocolate snack
Number of subjects: 26
Study: 19015329

Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (1,000/100 mg twice daily) alone for 14 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg once daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of saquinavir/ritonavir and ketoconazole
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (1,000/100 mg twice daily) with ketoconazole (200 mg once daily)
Number of subjects: 32
Study: 17314111

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 14722170

Group type: EXPERIMENTAL
Intervention: Intravenous morphine infusion of 10 micro g h(‐1) kg(‐1)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 3-hourly intravenous morphine boluses of 30 micro g kg(‐1)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 5 micro g h(‐1) kg(‐1) at birth (term neonates)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 8.5 micro g h(‐1) kg(‐1) at 1 month
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 13.5 micro g h(‐1) kg(‐1) at 3 months
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 18 micro g h(‐1) kg(‐1) at 1 year
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 16 micro g h(‐1) kg(‐1) for 1- to 3-yr-old children
Number of subjects: 184
Study: 11885871

Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nifedipine 10-20 mg twice daily
Number of subjects: 121
Study: 9554895

Group type: EXPERIMENTAL
Intervention: Early discharge (4 days after surgery with drain in situ)
Number of subjects: 125
Study: 8167511

Group type: EXPERIMENTAL
Intervention: 40 g of alcohol in the form of beer, wine, or spirits with dinner
Number of subjects: 8
Study: 3280148

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV) with halothane 1‐1.5% and N2O 66% in O2 (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controlled ventilation (IPPV) with halothane 0.5‐1%, N2O 66%, and pancuronium 0.05 mg.kg‐1 (n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controlled ventilation (IPPV)
Number of subjects: 120
Study: 31314073

Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with perfect adherence (daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with moderate adherence (4 doses/week)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with low adherence (2 doses/week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 30418053

Group type: EXPERIMENTAL
Intervention: Deep surgical site infection (SSI)
Number of subjects: 460
Study: 26960416

Group type: EXPERIMENTAL
Intervention: Matured hop extract (MHE) containing 35 mg MHBA, ingested daily for 12 weeks.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo beverage without MHE, ingested daily for 12 weeks.
Number of subjects: 200
Study: 25807170

Group type: EXPERIMENTAL
Intervention: Endoscopically harvested radial arteries
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventionally harvested radial arteries
Number of subjects: 66
Study: 22945605

Group type: EXPERIMENTAL
Intervention: Multi-component nutrition education intervention
Number of subjects: 8186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8186
Study: 20145176

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus lapatinib
Number of subjects: 580

Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 580
Study: 18984759

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (25 patients)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (26 patients)
Number of subjects: 51
Study: 15105215

Group type: EXPERIMENTAL
Intervention: Continuous low-frequency auricular electroacupuncture (1 Hz, 2 mA), n = 31
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional manual auricular acupuncture (sham-electroacupuncture), n = 30
Number of subjects: 61
Study: 11170151

Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (320 mg o.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9670433

Group type: EXPERIMENTAL
Intervention: HBO2 therapy at 2.5 atm abs pressure for 90 min daily for a total of five treatments, starting 1 h after the operation.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HBO2 therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no HBO2 therapy)
Number of subjects: 20
Study: 8194495

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) group (n = 16)
Number of subjects: 24
Study: 2980760

Group type: EXPERIMENTAL
Intervention: Medication M (Monobeltin) - 1,050 mg ASA with enteric coat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medication C (Colfarit) - 1,000 mg microencapsulated ASA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both medications
Number of subjects: 12
Study: 29985380

Group type: EXPERIMENTAL
Intervention: Para-articular oxygen/ozone therapy at a permanent ozone concentration of 8 gr/l (injection area 15-20 sq.cm)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Generic drug-based treatment alone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Para-articular oxygen/ozone therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combined treatment with oxygen/ozone therapy
Number of subjects: 89
Study: 27155232

Group type: EXPERIMENTAL
Intervention: 800 IU/day cholecalciferol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 1600 IU/day cholecalciferol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: UVB treatment (4.3-8.7 J/cm²)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (oral drops and Woods lamp)
Number of subjects: 114
Study: 25226912

Group type: EXPERIMENTAL
Intervention: 24 Ncm tightening group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 Ncm tightening group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 36 Ncm tightening group
Number of subjects: 30
Study: 23086704

Group type: EXPERIMENTAL
Intervention: Mild protocol (FSH 150 IU/day from day 4 followed by GnRH-antagonist from day 8; n=205)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Long protocol (FSH 150 IU/day; n=207)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Mild protocol
Number of subjects: 412

Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 412
Study: 20583915

Group type: COMPARATOR
Intervention: Open-flap debridement (OFD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with collagen membranes
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined treatment with autogenous periosteal membranes and autogenous bone chips (aCPRT)
Number of subjects: 42
Study: 18025536

Group type: EXPERIMENTAL
Intervention: ARC1779 (0.05 to 1.0 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16128862

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg day(-1) for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo for 12 weeks
Number of subjects: 18
Study: 11292279

Group type: EXPERIMENTAL
Intervention: Individuals with one or two long (l) 5HTTLPR alleles
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Individuals with one or two long (l) 5HTTLPR alleles or higher CSF 5HIAA levels
Number of subjects: 54

Group type: COMPARATOR
Intervention: s/s 5HTTLPR genotype
Number of subjects: 54
Study: 9389849

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v.
Number of subjects: 746

Group type: COMPARATOR
Intervention: metoclopramide 10 mg i.v.
Number of subjects: 746
Study: 8719005

Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost vaginal pessary administered at 6h intervals
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Epidural anesthetic
Number of subjects: 34
Study: 2906644

Group type: EXPERIMENTAL
Intervention: 0.5% Levobunolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% Timolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 40
Study: 31223153

Group type: EXPERIMENTAL
Intervention: Interviews with pharmacy faculty recognized for teaching excellence
Number of subjects: 9
Study: 28013352

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 25970116

Group type: EXPERIMENTAL
Intervention: Intravenous PTX 5 mg/kg/hr for 6 hours on 6 successive days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23234647

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21817943

Group type: EXPERIMENTAL
Intervention: Resorbable plate cranioplasty
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fat graft cranioplasty
Number of subjects: 71
Study: 19829036

Group type: EXPERIMENTAL
Intervention: IV midazolam (1 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No IV midazolam (control group)
Number of subjects: 50
Study: 16687909

Group type: EXPERIMENTAL
Intervention: Scanora panoramic radiography
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bitewing radiography
Number of subjects: 96
Study: 15561813

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 200 microg every 2 weeks (Q2W)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U weekly (QW)
Number of subjects: 312
Study: 11753772

Group type: EXPERIMENTAL
Intervention: PPF screw cup
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hedrocel pressfit cup
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cemented PE cup
Number of subjects: 80
Study: 9418619

Group type: EXPERIMENTAL
Intervention: Continuous passive motion starting at 70 degrees to 100 degrees flexion (Group I)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Continuous passive motion starting at 0 degrees to 30 degrees flexion (Group II)
Number of subjects: 210
Study: 8221741

Group type: EXPERIMENTAL
Intervention: Captopril pretreatment (6.25 mg orally 15 min before thrombolysis) in Group A
Number of subjects: 204

Group type: COMPARATOR
Intervention: Captopril late treatment (administered about 3 days after thrombolysis) in Group B
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Captopril pretreatment in Group A
Number of subjects: 204

Group type: COMPARATOR
Intervention: Captopril late treatment in Group B
Number of subjects: 204
Study: 30656782

Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tooth extraction
Number of subjects: 99

Group type: COMPARATOR
Intervention: Prophylaxis and topical fluoride (control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Previous dental appointment restraint
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Previous difficult behaviour
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Moment of measurement
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Dental caries on permanent teeth
Number of subjects: 99
Study: 29792230

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) support visits
Number of subjects: 172
Study: 27269054

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bOPV + Vitamin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPV only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPV + bOPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 0
Study: 24923524

Group type: EXPERIMENTAL
Intervention: Digital video assessment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Photography assessment
Number of subjects: 35
Study: 22072084

Group type: EXPERIMENTAL
Intervention: Ultrasound Disease Activity Score (US DAS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: DAS-28 (standard assessment)
Number of subjects: 90
Study: 20449752

Group type: EXPERIMENTAL
Intervention: Heat (31 degrees C + 70% rh)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heat + O(3) (31 degrees C + 70% rh + 0.10 ppm O(3))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (20 degrees C + 50% rh)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control + O(3) (20 degrees C + 50% rh + 0.10 ppm O(3))
Number of subjects: 10
Study: 18756983

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (clopidogrel 75 mg plus aspirin 100 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (low molecular weight heparin for 7 days plus long-term warfarin)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 16179787

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole for 2 days and 1 hour before the test
Number of subjects: 24

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 24
Study: 12540640

Group type: EXPERIMENTAL
Intervention: Chelation therapy with calcium disodium EDTA for 3 months followed by repeated therapy weekly for 24 months (32 patients with high-normal body lead burdens).
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo infusions for 5 weeks every 6 months (32 control patients).
Number of subjects: 202
Study: 10100068

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects (n = 289)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Untreated individuals
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Lowest quartile of AVP levels
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Subjects with low renin levels (< 10 mU/l; n = 118)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Patients receiving diuretics (n = 39)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Patients receiving beta-blockers (n = 54)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Patients receiving angiotensin-converting enzyme inhibitors (n = 9)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Patients receiving Ca(2+)-antagonists (n = 19)
Number of subjects: 534
Study: 8894198

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 2006235

Group type: EXPERIMENTAL
Intervention: Cytidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6344611

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Galactose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Water alone
Number of subjects: 20
Study: 29920980

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (5 mg, 10 mg, 20 mg, 40 mg, 80 mg)
Number of subjects: 40
Study: 30120529

Group type: EXPERIMENTAL
Intervention: FemoSeal™
Number of subjects: 155

Group type: COMPARATOR
Intervention: Perclose ProGlide®
Number of subjects: 155
Study: 27314581

Group type: EXPERIMENTAL
Intervention: Fortified biscuits with heme iron concentrate (n = 15)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fortified biscuits with iron sulfate (n = 19)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (biscuit control group, n = 13)
Number of subjects: 47
Study: 25166750

Group type: EXPERIMENTAL
Intervention: 3000 IU of oral cholecalciferol daily for 4 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22008309

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 19293312

Group type: EXPERIMENTAL
Intervention: CYP1B1 haplotype-tagging single nucleotide polymorphisms (rs9341266)
Number of subjects: 3125

Group type: EXPERIMENTAL
Intervention: CYP1B1 haplotypes
Number of subjects: 3125

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3125
Study: 17599630

Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide 0.1 microg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide 1 microg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide 10 microg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide (any dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide (1 patient, non-responder)
Number of subjects: 40
Study: 14701781

Group type: EXPERIMENTAL
Intervention: Methadone (7.5 mg orally every 12 hours and 5 mg every 4 hours as needed)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Morphine (15 mg sustained release every 12 hours and 5 mg every 4 hours as needed)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both Methadone and Morphine
Number of subjects: 103
Study: 11602266

Group type: EXPERIMENTAL
Intervention: Implementation of the Resident Assessment Instrument (RAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10396343

Group type: EXPERIMENTAL
Intervention: TrypTect CIATT
Number of subjects: 164

Group type: COMPARATOR
Intervention: Melarsoprol treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 164
Study: 7978143

Group type: EXPERIMENTAL
Intervention: Intravenous propofol infusion while breathing 100% oxygen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inhalational nitrous oxide, oxygen and halothane for maintenance of anaesthesia
Number of subjects: 80
Study: 2913769

Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 14

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 14
Study: 31116277

Group type: EXPERIMENTAL
Intervention: MTA only (MTA group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CH with saline (CH+saline group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CH with polyethylene glycol (CH+PEG group)
Number of subjects: 45
Study: 27824253

Group type: EXPERIMENTAL
Intervention: 3.5 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Number of subjects: 8
Study: 25926088

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (2,500 U)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: High-dose heparin (5,000 U)
Number of subjects: 490
Study: 23563076

Group type: EXPERIMENTAL
Intervention: Family Resilience Enhancement Program (FREP), 10 sessions over 5 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 34
Study: 21764398

Group type: EXPERIMENTAL
Intervention: Massage condition
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 49
Study: 19218138

Group type: EXPERIMENTAL
Intervention: Phosphocreatine treatment (8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 40
Study: 17031010

Group type: EXPERIMENTAL
Intervention: VF crispy bar
Number of subjects: 60

Group type: COMPARATOR
Intervention: Commercial crispy bars
Number of subjects: 60
Study: 12857504

Group type: EXPERIMENTAL
Intervention: BiPAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: IPPV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SIMV
Number of subjects: 30
Study: 10763145

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy
Number of subjects: 684

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 684
Study: 8988450

Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 272
Study: 1348777

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0